These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17509302)

  • 1. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
    J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Redfern CH; Fehrenbacher L; Saleh MN; Waterhouse DM; Carducci MA; Vicario D; Dreicer R; Higano CS; Ahmann FR; Chi KN; Henner WD; Arroyo A; Clow FW;
    J Clin Oncol; 2007 Feb; 25(6):669-74. PubMed ID: 17308271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
    Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
    J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
    Karampeazis A; Vamvakas L; Agelidou A; Kentepozidis N; Chainis K; Chandrinos V; Vardakis N; Pallis AG; Christophyllakis C; Georgoulias V
    Clin Lung Cancer; 2011 May; 12(3):155-60. PubMed ID: 21663857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
    Fosså SD; Jacobsen AB; Ginman C; Jacobsen IN; Overn S; Iversen JR; Urnes T; Dahl AA; Veenstra M; Sandstad B
    Eur Urol; 2007 Dec; 52(6):1691-8. PubMed ID: 17306441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ; Guerra ML; Kronish L
    Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
    Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
    Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD
    J Clin Oncol; 2004 Jul; 22(13):2532-9. PubMed ID: 15226321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
    J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
    Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
    Hahn NM; Marsh S; Fisher W; Langdon R; Zon R; Browning M; Johnson CS; Scott-Horton TJ; Li L; McLeod HL; Sweeney CJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6094-9. PubMed ID: 17062685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
    Vázquez S; Huidobro G; Amenedo M; Fírvida JL; León L; Lázaro M; Grande C; Mel JR; Ramos M; Salgado M; Casal J
    Anticancer Drugs; 2007 Nov; 18(10):1201-6. PubMed ID: 17893521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.